TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30556959
Drug: Miridesap 20
Normalized name: Miridesap
DrugBank: Miridesap (DB13087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miridesap 20 mg IV infusion
Study: 30556959
Drug: Miridesap 40
Normalized name: Miridesap
DrugBank: Miridesap (DB13087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miridesap 40 mg IV infusion
Study: 30556959
Drug: Miridesap 20
Normalized name: Miridesap
DrugBank: Miridesap (DB13087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miridesap 20 mg/h IV infusion (15-hour duration)
Study: 28926864
Drug: Conductive Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conductive Mitomycin C therapy (Combat ® and Unithermia ® devices)
Study: 26708124
Drug: Fluoxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (8 to 15 mg, titrated to weight)
Study: 24644106
Drug: Duloxetine 30-120
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30-120 mg once daily
Study: 9237705
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (125 mg, 250 mg, 500 mg daily for 14 days)
Study: 9237705
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (125 mg daily)
Study: 2448657
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (3 g/m2 iv weekly with leukovorin rescue)
Study: 2448657
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (30 mg/m2 orally weekly without rescue)
Study: 2448657
Drug: CAVP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAVP therapy
Study: 27567756
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of extended-release theophylline
Study: 22379743
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline nasal spray
Study: 18191847
Drug: Progesterone (P)
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone (P) only as luteal support (200 mg bid starting the following night after oocyte retrieval)
Study: 18191847
Drug: E(2) and
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E(2) and P combined (E(2) patches 100 microg/day twice per week starting on the day of embryo transfer with P)
Study: 16157525
Drug: Dipyridamole (0.74
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.74 mg/kg of body weight) used for coronary flow reserve assessment
Study: 14503903
Drug: Sling treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling treatment for shoulder dislocation
Study: 14503903
Drug: External rotation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External rotation treatment (splint or pillow)
Study: 8863556
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine daily for 1 week and 40 mg daily afterward (group 1)
Study: 8863556
Drug: 1 capsule
Normalized name: Cebocap 1 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule placebo daily for 1 week and 2 capsules daily afterward (group 2)
Study: 1407240
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day calcium supplement
Study: 18556898
Drug: Sensory integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory integration therapy program
Study: 16013898
Drug: Modafinil up
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil up to 200 mg a day (N = 13)
Study: 25842396
Drug: Atomized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomized lidocaine administered via intranasal mucosal delivery device
Study: 20497775
Drug: 10-g dose
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-g dose of oligofructose
Study: 20497775
Drug: 5-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-g dose of oligofructose
Study: 20497775
Drug: 10-g dose
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-g dose of native inulin
Study: 20497775
Drug: 5-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-g dose of native inulin
Study: 16176615
Drug: EGCG-caffeine mixtures
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG-caffeine mixtures (200 mg caffeine and variable doses of EGCG: 90, 200, 300, or 400 mg)
Study: 12949316
Drug: NFV 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFV 30 mg/kg TID
Study: 12949316
Drug: NFV 55
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFV 55 mg/kg BID
Study: 10755203
Drug: Celiprolol (200‐400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200‐400 mg daily)
Study: 10755203
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unchanged therapy)
Study: 9063232
Drug: Resin composite
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin composite with a dentinal bonding agent
Study: 6348986
Drug: 25% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% BCAA solution
Study: 21655317
Drug: Caregivers seeking
Normalized name: PAIN PALLIATION (BONE SEEKING AGENTS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregivers seeking treatment for child's fever
Study: 16752333
Drug: Cell infusion
Normalized name: irrigation set MISCELL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell infusion via a perfusion catheter with multiple side holes (SH-PC)
Study: 6734072
Drug: Intraluminal hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intraluminal hydrocortisone (100 mg/l)
Study: 6734072
Drug: Intraluminal hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intraluminal hydrocortisone (10 mg/l and 30 mg/l) followed by intravenous hydrocortisone
Study: 6734072
Drug: Intraluminal hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intraluminal hydrocortisone (100 mg/l) perfused with fructose and bicarbonate
Study: 25227544
Drug: Position one
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Position one wheelchair configuration (one inch of seat slope, solid backrest mounted at 105 degree seat to back angle, no solid seat insert with gel/foam contoured cushion)
Study: 21180218
Drug: Dinoprostone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (0.5 mg intracervically)
Study: 12941196
Drug: Systemic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic immunotherapy
Study: 6981575
Drug: Propranolol (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (continuous oral administration, dosage reducing heart rate by 25%)
Study: 31296586
Drug: Deutetrabenazine, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine, starting at 12 mg/day, titrated up to a maximum of 48 mg/day (36 mg/day for patients on strong CYP2D6 inhibitors).
Study: 22617579
Drug: Combination (clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (clomiphene citrate and metformin)
Study: 20650012
Drug: time‐contingent paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: time‐contingent paracetamol (4 g daily in divided doses)
Study: 20650012
Drug: PRN paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN paracetamol
Study: 15848538
Drug: Early cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early cessation of corticosteroid therapy
Study: 15848538
Drug: Long-term corticosteroid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term corticosteroid maintenance therapy
Study: 7622004
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy aimed at maintaining near-normal blood glucose values
Study: 7622004
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment regimen
Study: 2143145
Drug: Long-acting GnRH-a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting GnRH-a administered in early follicular phase (group A)
Study: 2143145
Drug: Long-acting GnRH-a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting GnRH-a administered in midluteal phase (group B)
Study: 735925
Drug: Physostigmine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (single dose)
Study: 735925
Drug: Physostigmine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (long-term treatment)
Study: 735925
Drug: Physostigmine (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (sustained treatment for 6 months)
Study: 735925
Drug: Physostigmine (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (sustained treatment for 6 to 36 months)
Study: 28926440
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 0 μg/ml
Study: 28926440
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 1 μg/ml
Study: 28926440
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 2 μg/ml
Study: 28926440
Drug: Cumulative fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cumulative fentanyl dose
Study: 20632302
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (taping, strengthening, stretching)
Study: 17144784
Drug: Selective serotonin-reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin-reuptake inhibitors
Study: 8187005
Drug: Six weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Six weekly doses of carboplatin concurrent with radiotherapy
Study: 31115690
Drug: Intrapapillary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapapillary injection (IPI)
Study: 31573398
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation during 0.55 T MRI
Study: 25929711
Drug: Chin cup
Normalized name: CHIN-UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chin cup treatment
Study: 23521503
Drug: GSK239512 (5/10/20/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK239512 (5/10/20/40 μg and 10/20/40/80 μg regimens)
Study: 23521503
Drug: GSK239512 (20/40/80/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK239512 (20/40/80/150 μg regimen)
Study: 16875470
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Contractubex gel)
Study: 9024032
Drug: Epidural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural dexamethasone (1 mL, 5 mg) with 25 mL 2% lidocaine and epinephrine 1:200,000
Study: 8395488
Drug: Low-dose Lisinopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Lisinopril
Study: 30412993
Drug: Nature-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nature-Based Therapy (NBT)
Study: 26154154
Drug: Sequential intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intermittent pneumatic compression (SIPC)
Study: 19827029
Drug: 5% extract
Normalized name: COAL TAR 5% EXTRACT TOP STICK
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% extract of Solidago chilensis applied externally as a gel, two daily applications for 15 days
Study: 19827029
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied externally, two daily applications for 15 days
Study: 11975091
Drug: Reboxetine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (2 x 2 mg)
Study: 11471032
Drug: alpha‐IFN treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐IFN treatment
Study: 8732235
Drug: Acarosan treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarosan treatment and bedding covers
Study: 8732235
Drug: Acarosan treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarosan treatment
Study: 1374201
Drug: Diclofenac (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (0.35 mg.kg‐1 bolus followed by a constant‐rate infusion of 90 micrograms.min‐1 for 24 h)
Study: 3926667
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone (1 ml Decadronphosphate)
Study: 30770780
Drug: Methylphenidate (MP)
Normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MP) 0.5 mg/kg, i.v.
Study: 27269942
Drug: Pertuzumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks)
Study: 27269942
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus chemotherapy
Study: 16472719
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (60 g of ethanol)
Study: 8918401
Drug: Oral levo-leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levo-leucovorin (1-leucovorin) 25 mg/dose followed by oral 5-dFUR 750 mg/m2 twice daily for 4 days every 12 days (arm A)
Study: 8918401
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) 1-leucovorin 25 mg/dose followed by i.v. 5-dFUR 3000 mg/m2 for 5 days every 21 days (arm B)
Study: 2981515
Drug: Intermittent long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent long-term combined chemotherapy (ILTCC) with immunotherapy
Study: 2981515
Drug: Continuous long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous long-term combined chemotherapy (CLTCC) with immunotherapy
Study: 2981515
Drug: Short-term combined
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term combined chemotherapy (STCC)
Study: 23263261
Drug: Supervised medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised medical exercise therapy
Study: 21309475
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg/day) in healthy subjects
Study: 21309475
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg/day) in patients with a stent
Study: 10539831
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d tranilast
Study: 10539831
Drug: 300 mg/d
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/d tranilast
Study: 8557899
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg once daily)
Study: 8557899
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (metoprolol + nifedipine)
Study: 6285406
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg delta 9‐THC
Study: 6285406
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of 0.5 mg/kg delta 9‐THC and 1 mg/kg CBD
Study: 24830749
Drug: Daily Co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Co-trimoxazole (CTX)
Study: 15939311
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 microg once daily (o.d.)
Study: 15939311
Drug: Ciclesonide 640
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 640 microg once daily (o.d.)
Study: 15939311
Drug: Ciclesonide 640
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 640 microg twice daily (b.i.d.)
Study: 15939311
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 440 microg twice daily (b.i.d.)
Study: 15939311
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 880 microg twice daily (b.i.d.)
Study: 14568851
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor treatment
Study: 14568851
Drug: Conventional topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional topical treatment
Study: 10930151
Drug: ALVAC‐HIV followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC‐HIV followed by the protein vaccine
Study: 8653191
Drug: Cost recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost recovery intervention with improved drug supply in Say and Boboye
Study: 25150159
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 units · mL(‐1) (Gla‐300) at 0.4 units · kg(‐1)
Study: 25150159
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units · mL(‐1) (Gla‐100) at 0.4 units · kg(‐1)
Study: 24511720
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 1 microg/kg
Study: 24511720
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 1 ml/10 kg
Study: 12838218
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of polyethylene glycol-electrolyte solution, one tablet of bisacodyl, and a minimally restricted diet on the day before colonoscopy, and then 1 L of the same solution on the day of colonoscopy (Group B)
Study: 12838218
Drug: 3 L
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 L of polyethylene glycol-electrolyte solution with a liquid diet on the day before colonoscopy (Group A)
Study: 10834779
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.1% bupivacaine + fentanyl (3 microg/mL) at 5 mL/h
Study: 8436747
Drug: Zofenopril (angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril (angiotensin-converting enzyme inhibitor)
Study: 3017605
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg b.d.)
Study: 31468364
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to MAS therapy
Study: 27840477
Drug: Classic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic treatment (control)
Study: 18257180
Drug: Medication (Mecobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Mecobalamin tablets)
Study: 15927394
Drug: Duloxetine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (all active treatment groups)
Study: 6988748
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (31 patients) receiving no prophylactic antibiotics
Study: 25581505
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control treatment strategy
Study: 25581505
Drug: Good treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good treatment strategy
Study: 25581505
Drug: Good medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good medication
Study: 9085316
Drug: Vancomycin 1000
Normalized name: vancomycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1000 mg infused during the last hour of hemodialysis with cellulose triacetate (CT) hemodialyzer
Study: 9085316
Drug: Vancomycin 1000
Normalized name: vancomycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1000 mg infused during the last hour of hemodialysis with cellulose acetate (CA) hemodialyzer
Study: 9085316
Drug: Vancomycin 1000
Normalized name: vancomycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1000 mg infused after dialysis was completed (control)
Study: 3566858
Drug: Fendiline hydrochloride
Normalized name: fendiline hydrochloride
DrugBank: Fendiline (DB08980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendiline hydrochloride 200 mg, 400 mg, 600 mg, 800 mg, 1000 mg, 1200 mg (single doses)
Study: 3566858
Drug: Fendiline hydrochloride
Normalized name: fendiline hydrochloride
DrugBank: Fendiline (DB08980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendiline hydrochloride 400 mg twice daily (initially), reduced to 200 mg twice daily after 5 days due to intolerability
Study: 3566858
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 subjects per dose level in the first study and 3 subjects in the second study)
Study: 15766375
Drug: 0.12% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% CHX non-alcohol base with 0.05% cetyl pyridinium chloride (Cpc) mouthrinse (Perioaid), 15 ml, twice daily for 30 s
Study: 15766375
Drug: 0.2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% CHX alcohol base (Corsodyl), 10 ml, twice daily for 60 s